688068
vs
S
Shanghai Composite
688068
Over the past 12 months, Beijing Hotgen Biotech Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +133% compared to the Shanghai Composite's +23% growth.
Stocks Performance
688068 vs Shanghai Composite
Performance Gap
688068 vs Shanghai Composite
Performance By Year
688068 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Beijing Hotgen Biotech Co Ltd
Glance View
Beijing Hotgen Biotech Co., Ltd. engages in the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The company is headquartered in Beijing, Beijing and currently employs 1,019 full-time employees. The company went IPO on 2019-09-30. The firm's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The firm primarily conducts its businesses in domestic and overseas markets.
